@article {Trindade43, author = {Patr{\'\i}cia Trindade and Alice Gelpi and Ana Salgado and Joana Marto and Paula Machado and Dinis Mateus and Humberto Gon{\c c}alves and M Fernanda Sachse and Ant{\'o}nio Melo Gouveia and Helena Ribeiro}, title = {Betamethasone dipropionate compounding for cutaneous T-cell lymphoma management}, volume = {25}, number = {1}, pages = {43--47}, year = {2018}, doi = {10.1136/ejhpharm-2016-001052}, publisher = {BMJ Specialist Journals}, abstract = {Background Primary cutaneous lymphomas (extranodular non-Hodgkin lymphomas) are rare (incidence 1:100 000). Mycosis fungoides is the most common cutaneous T-cell lymphoma (CTCL) subtype. Treatment options are based on the diagnosis and the stage of the disease. Skin-directed therapies are useful for the initial stages and include topical treatments such as corticosteroids. Betamethasone dipropionate (BD) is a synthetic glucocorticoid with high anti-inflammatory activity, potency and immunosuppressant effects. It is used for topical treatment of CTCL within the following dosage 0.025{\textendash}0.1\% (w/w). In the Portuguese market only one topical cream contains BD at 0.05\% (w/w).Objectives To develop a new and stable emulsion containing 0.1\% of BD.Methods To accomplish this aim, development, stability, in vitro release and clinical studies of a new topical water-in-oil emulsion containing BD 0.1\% w/w were assessed for the topical treatment of CTCL.Results The three batches prepared were physically, chemically and microbiologically stable over a period of 90 days. 40\% of BD was released over 6 hours and evaluation of skin lesions showed a favourable clinical effect (less itching, less infiltration, fewer patches and a reduced area of plaque).Conclusions The clinical results show the effective cutaneous improvement of skin barrier conditions during the study.}, issn = {2047-9956}, URL = {https://ejhp.bmj.com/content/25/1/43}, eprint = {https://ejhp.bmj.com/content/25/1/43.full.pdf}, journal = {European Journal of Hospital Pharmacy} }